Press Releases

AssistRx Delivers Enhanced ePrior Authorization


ORLANDO, Fla., Oct. 16, 2018 (GLOBE NEWSWIRE) — AssistRx (ARx), the leading digital technology platform focused on connecting the healthcare ecosystem to improve access to prescribed therapies, announces a major enhancement to its ePrior Authorization (ePA) Acceleration Service within the company’s flagship product, iAssist. iAssist accelerates patient access to specialty medications through configurable web-based workflows and powerful integrations with pharmacies, hubs and electronic medical record (EMR) systems.

iAssist integrations with two leading ePA service partners enable rapid connectivity to pharmacy benefit managers (PBMs) and payers, meaning PA decisions can be returned within minutes from capable PBMs and payers. As a result, PA decisions are returned faster and with less effort, patients gain access to prescribed therapies sooner, and prescribers benefit from a simplified process and reduction in the back-and-forth associated with the typical reactive PA process.

According to a recent study by the American Medical Association (AMA), providers receive an average of 29.1 PA requests each week, and providers and office staff spend an average of 14.6 hours each week completing their PA workload. Other AMA research found that 40 percent of claims rejected at pharmacies are abandoned.

In other words, providers’ offices handle a lot of PAs, they take a lot of time, and if they’re not done right, those prescriptions may be abandoned.

“We continuously innovate and expand our partnerships across the healthcare ecosystem to alleviate these kinds of burdens and improve the patient journey,” said Jeff Spafford, CEO and president of AssistRx. “Our enhanced ePA Acceleration Service achieves these objectives by streamlining the PA process, enabling rapid connectivity for faster PA decisions, and allowing prescribers to digitally complete PAs prospectively, accurately and completely-all in one place.”

Through integrations with its partners, iAssist supports more than 80 percent of payer covered lives. PA questions and response options mirror the actual PA form and are populated directly in the iAssist workflow. This eliminates the submission of forms with missing, inaccurate or incomplete information and improves ease of use. For the remaining 20 percent not covered by partner integrations, iAssist’s ePA Acceleration Service is complemented by a digital PA library of more than 20,000 up-to-date PA forms. iAssist’s bi-directional communication allows prescribers to receive up-to-the-minute status updates on PA requests (ePA and fax) directly in iAssist.

Recognizing that the PA process is just one of many steps involved in specialty medication enrollments, iAssist’s additional Acceleration Services include ePrescribing, eEligibility, eConsent, Financial Assistance, eEnrollment, Additional Patient Services and Pharmacy Selection.

For more information about the company, visit

About AssistRx
AssistRx believes that access to therapy transforms lives and is achieved through the powerful combination of our people and technology. We are the trusted partner to deliver leading technology and people solutions that connect every stakeholder. Our solutions accelerate patient access to therapy and improve outcomes.

The AssistRx Platform is a HIPAA compliant, secure, cloud-based platform that allows for the configuration of patient access workflows. This open technology platform connects manufacturers’ various partners. Through our flagship product, iAssist, Acceleration Services are tailored to the business and therapy needs of specific brands, and significantly impact the prescribers’ and patients’ experience in accessing those brands. Knowing technology only effectively supports a portion of the patient journey, we combine our cutting-edge technology platform with human expertise to offer optimal support to prescribers and patients. Our best-in-class, tech-enabled ARx Patient Solutions team offers quality, cost-effective solutions that are individualized to meet life sciences companies’ needs. For additional information, visit